Summit Therapeutics (SMMT) jumps as investors refocus on upcoming ivonescimab data and bullish recent coverage

Summit Therapeutics (SMMT) is up 6.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed attention on ivonescimab (Summit’s lead oncology program) ahead of upcoming scientific disclosures, alongside a recent wave of bullish sell-side coverage. Elevated short interest may also be amplifying upside volatility as incremental buyers show up.

Details:

Summit recently said multiple data sets from Phase III studies of ivonescimab in advanced non-small cell lung cancer patient populations are scheduled to be presented at the 2026 European Lung Cancer Congress (ELCC), including an intracranial efficacy-focused poster from the global HARMONi study.

Earlier in April, a major Wall Street firm initiated coverage on Summit, which can draw new institutional attention and drive price action even without same-day company news.

Public short-interest data (as of March 31, 2026) shows a large short position relative to float; that setup can contribute to sharper intraday rallies when volume increases.

No new Summit press release or SEC filing dated April 21, 2026 appears to clearly explain the single-day jump, so momentum and positioning likely played a role.

Sources:

Summit Therapeutics, MarketBeat, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$SMMT Insider Trading Activity

$SMMT insiders have traded $SMMT stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $SMMT stock by insiders over the last 6 months:

YU XIA purchased 533,617 shares for an estimated $9,999,982
ROBERT W DUGGAN (Co-Chief Executive Officer) purchased 26,680 shares for an estimated $499,983
MAHKAM ZANGANEH (Co-Chief Executive Officer) purchased 26,680 shares for an estimated $499,983

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$SMMT Hedge Fund Activity

We have seen 115 institutional investors add shares of $SMMT stock to their portfolio, and 123 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 4,832,592 shares (+106.5%) to their portfolio in Q4 2025, for an estimated $84,522,034
FMR LLC added 4,442,920 shares (+49.8%) to their portfolio in Q4 2025, for an estimated $77,706,670
BAKER BROS. ADVISORS LP added 2,668,089 shares (+7.9%) to their portfolio in Q4 2025, for an estimated $46,664,876
CITADEL ADVISORS LLC added 2,272,996 shares (+1121.3%) to their portfolio in Q4 2025, for an estimated $39,754,700
BLACKROCK, INC. added 1,998,128 shares (+27.1%) to their portfolio in Q4 2025, for an estimated $34,947,258
MORGAN STANLEY removed 1,000,249 shares (-51.9%) from their portfolio in Q4 2025, for an estimated $17,494,355
FIERA CAPITAL CORP removed 762,094 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,329,024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$SMMT Analyst Ratings

Wall Street analysts have issued reports on $SMMT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citizens issued a "Market Outperform" rating on 01/30/2026

To track analyst ratings and price targets for $SMMT, check out Quiver Quantitative's $SMMT forecast page.

$SMMT Price Targets

Multiple analysts have issued price targets for $SMMT recently. We have seen 5 analysts offer price targets for $SMMT in the last 6 months, with a median target of $30.0.

Here are some recent targets:

Dara Azar from Stifel set a target price of $45.0 on 04/08/2026
Clara Dong from Jefferies set a target price of $15.0 on 03/16/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $30.0 on 02/24/2026
Reni J. Benjamin from Citizens set a target price of $40.0 on 01/30/2026
Etzer Darout from Barclays set a target price of $18.0 on 12/17/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.